First Oral Long-Acting ADHD Stimulant Treatment To Have Efficacy Data for Adults at 14-hours Postdose in Product Labeling
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Acting, Adhd, Adhd Treatment, Adults, Efficacy Data, Fda, Lisdexamfetamine Dimesylate, Product Labeling, Stimulant Treatment, Supplemental Data, Vyvanse
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse®
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adhd Treatment, Attention Deficit Hyperactivity Disorder, Company Today Announced That, Fda, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Hyperactivity, Lisdexamfetamine Dimesylate, Lse, Nasdaq, Prescribing Information, Shp, Supplemental Data, Today Announced That, Us Food And Drug Administration, Vyvanse
LONDON (SHARECAST) - Pharmaceutical group Shire saw sales and earnings fall in the first quarter of 2010 as its ADHD treatment Adderall felt the impact of competition following the expiration of its exclusivity.
Get information about a treatment option for adults with ADHD.
Save on an ADHD treatment from a leading ADHD pharmaceutical company
